When Everyone Is an Orphan: Against Adopting a U.S.-Styled Orphan Drug Policy in Canada

REFERENCES

• Abraham , J. and Sheppard , J. 1999 . Complacent and conflicting scientific expertise in British and American drug regulation: Clinical risk assessment of Triazolam.” . Social Studies of Science , 29 ( 6 ) : 803 – 843 .
   PubMed Web of Science ®Google Scholar
• Anon. (2012). Tories chose patent protection over children's lives in defeating drug bill: Stephen Lewis. The Globe and Mail. http://www.theglobeandmail.com/news/politics/tories-chose-patent-protection-over-childrens-lives-in-defeating-drug-bill-stephen-lewis/article5827019/ (http://www.theglobeandmail.com/news/politics/tories-chose-patent-protection-over-childrens-lives-in-defeating-drug-bill-stephen-lewis/article5827019/) (Accessed: 8 December 2012 ).
   Google Scholar
• Arno , P. S. , Bonuck , K. and Davis , M. 1995 . Rare diseases, drug development, and AIDS: The impact of the Orphan Drug Act . The Milbank Quarterly , 73 ( 2 ) : 231 – 252 .
   PubMed Web of Science ®Google Scholar
• Avard, D., Bucci, L., Burgess, M., Kaye, J., Heeney, C., Farmer, Y., and Cambon-Thomsen, A. (2009). Public Health Genomics (PHG) and public participation: Points to consider. Journal of Public Deliberation, 5(1). http://www.publicdeliberation.net/jpd/vol5/iss1/art7 (http://www.publicdeliberation.net/jpd/vol5/iss1/art7) (Accessed: 11 June 2013 ).
   Google Scholar
• Baker , D. 2008 . The benefits and savings from publicly funded clinical trials of prescription drugs . International Journal of Health Services: Planning, Administration, Evaluation , 38 ( 4 ) : 731 – 750 .
   PubMed Web of Science ®Google Scholar
• Banerjee , A. , Hollis , A. and Pogge , T. 2010 . The health impact fund: Incentives for improving access to medicines . The Lancet , 375 ( 9709 ) : 166 – 169 .
   PubMed Web of Science ®Google Scholar
• Baylis, F. (2012). Knowledge: The Best Return on Investment: The Mark News.” http://www.themarknews.com/articles/8299-knowledge-the-best-return-on-investment/#.UPsL2OjNCt4 (http://www.themarknews.com/articles/8299-knowledge-the-best-return-on-investment/#.UPsL2OjNCt4) (Accessed: 19 January 2013 ).
   Google Scholar
• Beltrame, J. Will Canada-EU Trade Deal Keep Generic Drugs Off Shelves?” The Huffington Post. http://www.huffingtonpost.ca/2012/09/16/canada-eu-trade-drug-patents_n_1888492.html (http://www.huffingtonpost.ca/2012/09/16/canada-eu-trade-drug-patents_n_1888492.html) (Accessed: 19 January 2013 ).
   Google Scholar
• 2010 . Biologics Price Competition and Innovation Act. , Pub. L. No. 111-148, § 7001, 124 Stat. 804, codified at 42 U.S.C. §262(k)(7)(A)
   Google Scholar
• Bohrer , R. A. and Prince , J. T. 1999 . A tale of two proteins: The FDA's uncertain interpretation of the Orphan Drug Act . Harvard Journal of Law and Technology , 12 : 365 – 417 .
   Google Scholar
• Canada . April 14 2008 . House of Commons April 14 , 4847 – 4849 . Debates 142, no. 078, 2d Session, 39th Parliament. 2008
   Google Scholar
• Canadian Cancer Society. (2012). Breast cancer statistics at a glance. http://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2012—English.pdf (http://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2012—English.pdf) (Accessed: 11 June 2013 ).
   Google Scholar
• Canadian Organization for Rare Disorders. (CORD). (2013). News and Events. http://raredisorders.ca/newsEvents.html (http://raredisorders.ca/newsEvents.html) (Accessed: 11 June 2013 ).
   Google Scholar
• Canadian Organization for Rare Disorders. (CORD). (2005). Position Paper on Canada's Orphan Drug Policy. http://raredisorders.ca/currentIssues.html (http://raredisorders.ca/currentIssues.html) (Accessed: 11 June 2013 ).
   Google Scholar
• Carey , K. 2012 . Avastin loses breast cancer indication . Nat.Biotech. , 30 ( 1 ) : 6
   PubMedGoogle Scholar
• Carey , K. 2011 . Biosimilars encircle Rituxan, US debates innovator exclusivity . Nat.Biotech. , 29 ( 3 ) : 177 – 178 .
   PubMed Web of Science ®Google Scholar
• Carpenter , D. and Fendrick , M. 2004 . Accelerating approval times for new drugs in the U.S . The Regulatory Affairs Journal–-Pharma , 15 ( 6 ) : 411 – 417 .
   Google Scholar
• Cheung , R. Y. , Cohen , J. C. and Illingworth , P. 2004 . Orphan Drug Policies: Implications for the United States, Canada, and Developing Countries . Health Law Journal , 12 : 183 – 200 .
   PubMedGoogle Scholar
• Coles , L. D. and Cloyd , J. C. 2012 . The role of academic institutions in the development of drugs for rare and neglected diseases . Clinical Pharmacology and Therapeutics , 92 ( 2 ) : 193 – 202 .
   PubMed Web of Science ®Google Scholar
• Coté , T. R. , Xu , K. and Pariser , A. R. 2010 . Accelerating orphan drug development . Nature Reviews.Drug Discovery , 9 ( 12 ) : 901 – 902 .
   PubMed Web of Science ®Google Scholar
• Coté , T. , Kelkar , A. , Xu , K. , Braun , M. M. and Phillips , M. I. 2010 . Orphan products: An emerging trend in drug approvals . Nature Reviews Drug Discovery , 9 ( 1 ) : 84 – 84 .
   PubMed Web of Science ®Google Scholar
• Daniels , N. 2000 . Accountability for reasonableness . BMJ , 321 ( 7272 ) : 1300 – 1301 .
   PubMed Web of Science ®Google Scholar
• Daniels , N. and Sabin , J. 1997 . Limits to health care: Fair procedures, democratic deliberation, and the legitimacy problem for insurers . Philosophy and Public Affairs , 26 ( 4 ) : 303 – 350 .
   PubMed Web of Science ®Google Scholar
• Davis , J. C. , Furstenthal , L. , Desai , A. A. , Norris , T. , Sutaria , S. , Fleming , E. and Ma , P. 2009 . The microeconomics of personalized medicine: Today's challenge and tomorrow's promise . Nature Reviews Drug Discovery , 8 ( 4 ) : 279 – 286 .
   PubMed Web of Science ®Google Scholar
• Deverka , P. A. , Vernon , J. and McLeod , H. L. 2010 . Economic opportunities and challenges for pharmacogenomics . Annual Review of Pharmacology and Toxicology , 50 ( 1 ) : 423 – 437 .
   PubMedGoogle Scholar
• Directive 2004/27/EC of the European Parliament and the Council of 31 March 2004 amending Directive 2001/83/EC on the Community Code relating to medicinal products for human use. Office Journal of the European Union L136, 30/4/2004, P.0034-0057.
   Google Scholar
• 1984 . Drug Price Competition and Patent Term Restoration Act United States 98th Congress, P.L. 98-417, 98 Stat. 1585
   Google Scholar
• Drummond , M. , Evans , B. , LeLorier , J. , Karakiewicz , P. , Martin , D. , Tugwell , P. and MacLeod , S. 2009 . Evidence and values: Requirements for public reimbursement of drugs for rare diseases: A case study in oncology . The Canadian Journal of Clinical Pharmacology (Journal Canadien De Pharmacologie Clinique) , 16 ( 2 – ) : 282 – 284 . e273 – e281 . discussion
   Google Scholar
• Drummond , M. F. , Wilson , D. A. , Kanavos , P. , Ubel , P. and Rovira , J. 2007 . Assessing the economic challenges posed by orphan drugs . International Journal of Technology Assessment in Health Care , 23 ( 1 ) : 36 – 42 .
   PubMed Web of Science ®Google Scholar
• Dunkle , M. , Pines , W. and Saltonstall , P. L. 2010 . Advocacy groups and their role in rare diseases research . Advances in Experimental Medicine and Biology , 686 : 515 – 525 .
   PubMed Web of Science ®Google Scholar
• Elliott , R. 2007 . Delivering on the pledge: Global access to medicines, WTO rules, and reforming Canada's Law on Compulsory Licensing for Export . McGill International Journal of Sustainable Development Law and Policy , 3 : 23 – 67 .
   Google Scholar
• European Commission. (EC). (2000a). Regulation 141/2000, 2000 O.J. (L18) 1-5 (EC) of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products
   Google Scholar
• European Commission. (EC). (2000b). Regulation 847/2000, 2000 O.J. (L103) 5-8 (EC)
   Google Scholar
• European Patent Convention, 5 October 1973, 1065 U.N.T.S. 199, art. 63(2)(b)
   Google Scholar
• Feick, K. (2010). Frost & Sullivan: Orphan Drugs to Create Paradigm Shift in the Pharmaceutical Industry! http://www.frost.com/prod/servlet/press-release.pag?docid=197715735 (http://www.frost.com/prod/servlet/press-release.pag?docid=197715735) (Accessed: 23 January 2013 ).
   Google Scholar
• Fernandez , C. V. 2007 . Our moral obligations in caring for patients with orphan cancers . CMAJ: Canadian Medical Association Journal , 176 ( 3 ) : 297
   PubMed Web of Science ®Google Scholar
• Flood , C. M. and Dyke , P. 2012 . The data divide: Managing the misalignment in Canada's evidentiary requirements for drug regulation and funding . UBC Law Review , 45 ( 2 ) : 283 – 328 .
   Google Scholar
• Food and Drug Administration. (FDA). (2013). Designating an Orphan Product: Drugs and Biologics: Common EMEA/FDA Application for Orphan Medicinal Product Designation. WebContent. http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/ucm124795.htm (http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/ucm124795.htm) (Accessed: 23 January 2013 ).
   Google Scholar
• Food and Drug Administration. (FDA). (2012). Research, Center for Drug Evaluation and “Biosimilars” WebContent. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htm (http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htm) (Accessed: 31 December 2012 ).
   Google Scholar
• Food and Drug Administration. (FDA). (2011). Orphan Drug Regulations: Proposed Rules, 76 Fed. Reg. 64868–64879
   Google Scholar
• Food and Drug Administration. (FDA). (1986). Policy of Eligibility of Drugs for Orphan Designation, 51 Fed. Reg. 4505
   Google Scholar
• Food and Drug Regulations. (Canada). (1985). C.R.C., c. 870, C.08.004.1
   Google Scholar
• Galloway, G. (2012). Tories block bid to make cheaper medicines for poor nations. The Globe and Mail. http://www.theglobeandmail.com/news/politics/tories-block-bid-to-make-cheaper-medicines-for-poor-nations/article5759286/ (http://www.theglobeandmail.com/news/politics/tories-block-bid-to-make-cheaper-medicines-for-poor-nations/article5759286/) (Accessed: 29 December 2012 ).
   Google Scholar
• Gericke , C.A. , Riesberg , A. and Busse , R. 2005 . Ethical issues in funding orphan drug research and development . Journal of Medical Ethics , 31 ( 3 ) : 164 – 168 .
   PubMed Web of Science ®Google Scholar
• Global Genes Project. (2012). Who We Are. http://globalgenes.org/who-we-are-2/ (http://globalgenes.org/who-we-are-2/) (Accessed: 11 June 2013 ).
   Google Scholar
• Grootendorst , P. , Hollis , A. , Levine , D. K. , Pogge , T. and Edwards , A. M. 2011 . New approaches to rewarding pharmaceutical innovation . CMAJ: Canadian Medical Association Journal (Journal De l'Association Medicale Canadienne , 183 ( 6 ) : 681 – 685 .
   PubMed Web of Science ®Google Scholar
• Gupta , S. 2012 . Rare diseases: Canada's ‘research orphans . Open Medicine , 6 ( 1 ) : 24 – 27 .
   Google Scholar
• Haffner , M. E. 2006 . Adopting orphan drugs: Two dozen years of treating rare diseases . The New England Journal of Medicine , 354 ( 5 ) : 445 – 447 .
   PubMed Web of Science ®Google Scholar
• Haffner , M. E. , Torrent-Farnell , J. and Maher , P. D. 2008 . Does orphan drug legislation really answer the needs of patients? . The Lancet , 371 ( 9629 ) : 2041 – 2044 .
   PubMed Web of Science ®Google Scholar
• Harper , A. R. and Topol , E. J. 2012 . Pharmacogenomics in clinical practice and drug development . Nature Biotechnology , 30 ( 11 ) : 1117 – 1124 .
   PubMed Web of Science ®Google Scholar
• Health Canada. (2012a). An Orphan Drug Framework for Canada - Health Canada News Release 2012-10-03. Media release, August 3, 2012. http://www.hc-sc.gc.ca/ahc-asc/media/nr-cp/_2012/2012-147a-eng.php (http://www.hc-sc.gc.ca/ahc-asc/media/nr-cp/_2012/2012-147a-eng.php)
   Google Scholar
• Health Canada. (2012b). Federal Government Takes Action to Help Canadians with Rare Diseases. Health Canada News Release 2012-10-03. Media release, October 3, 2012. http://www.hc-sc.gc.ca/ahc-asc/media/nr-cp/_2012/2012-147-eng.php (http://www.hc-sc.gc.ca/ahc-asc/media/nr-cp/_2012/2012-147-eng.php)
   Google Scholar
• Health Canada. (1997a). Policy Issues: Orphan Drug Policy. Correspondence, January 16, 1997. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/pol/orph_pol-eng.php (http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/pol/orph_pol-eng.php)
   Google Scholar
• Health Canada. (1997b). Guidance for Industry: Good Clinical Practice: Consolidated Guideline: ICH Topic E6” Notice, September 19, 1997. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/ich/efficac/e6-eng.php (http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/ich/efficac/e6-eng.php)
   Google Scholar
• ICH. (1996). Guideline for Good Clinical Practice. European Union, Japan and USA (1996). http://www.cinme.com.ar/english/lecturas/ICH_E6_Guias_BPC.pdf (http://www.cinme.com.ar/english/lecturas/ICH_E6_Guias_BPC.pdf) (Accessed: 11 June 2013 ).
   Google Scholar
• Heemstra , H. E. , Giezen , T. J. , Mantel-Teeuwisse , A. K. , de Vrueh , R. L. A. and Leufkens , H. G. M. 2010 . Safety-related regulatory actions for orphan drugs in the US and EU: A cohort study . Drug Safety: An International Journal of Medical Toxicology and Drug Experience , 33 ( 2 ) : 127 – 137 .
   PubMed Web of Science ®Google Scholar
• Heemstra , H. E. , van Weely , S. , Büller , H. A. , Leufkens , H. G. M. and de Vrueh , R. L. A. 2009 . Translation of rare disease research into orphan drug development: Disease matters . Drug Discovery Today , 14 ( 23–24 ) : 1166 – 1173 .
   PubMed Web of Science ®Google Scholar
• Hemphill , T. A. 2010 . Extraordinary pricing of orphan drugs: Is it a socially responsible strategy for the U.S. pharmaceutical industry? . Journal of Business Ethics , 94 ( 2 ) : 225 – 242 .
   Web of Science ®Google Scholar
• Herder , M. 2012a . Unlocking Health Canada's cache of trade secrets: Mandatory disclosure of clinical trial results . CMAJ: Canadian Medical Association Journal (Journal De l'Association Medicale Canadienne) , 184 ( 2 ) : 194 – 199 .
   PubMed Web of Science ®Google Scholar
• Herder , M. 2012b . Choice patents . IDEA: The Intellectual Property Law Review , 52 ( 3 ) : 309 – 378 .
   Google Scholar
• Herder , M. 2009 . Patents and the progress of personalized medicine: Biomarkers research as lens . Annals of Health Law/Loyola University Chicago, School of Law, Institute for Health Law , 18 ( 2 ) : 187 – 229 . 8 p. preceding i
   PubMedGoogle Scholar
• Hohl , C. M. , Nosyk , B. , Kuramoto , L. , Zed , P. J. , Brubacher , J. R. , Abu-Laban , R. B. , Sheps , S. B. and Sobolev , B. 2011 . Outcomes of emergency department patients presenting with adverse drug events . Annals of Emergency Medicine , 58 ( 3 ) : 270 – 279 . e4
   PubMed Web of Science ®Google Scholar
• Hollis , A. 2007 . Drugs for rare diseases: Paying for innovation. In: Beach, C. M., Chaykowski, R., Shortt, S., St-Hilaire, F., and Sweetman, A. (eds.) . Health services restructuring in Canada: New evidence and new directions , Kingston, Ontario, Canada: McGill-Queen's Press-MQUP, 155–177
   Google Scholar
• Huyard , C. 2009 . How did uncommon disorders become ‘rare diseases’? History of a boundary object . Sociology of Health and Illness , 31 ( 4 ) : 463 – 477 .
   PubMed Web of Science ®Google Scholar
• Japan. Ministry of Health, Labour and Welfare. (2009). Overview of Orphan Drug/Medical Device Designation System. http://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/orphan_drug.html (http://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/orphan_drug.html)
   Google Scholar
• Jayadev , A. and Stiglitz , J. 2009 . Two ideas to increase innovation and reduce pharmaceutical costs and prices . Health Affairs , 28 ( 1 ) : w165 – w168 .
   Web of Science ®Google Scholar
• Kesselheim , A. S. 2011 . An empirical review of major legislation affecting drug development: Past experiences, effects, and unintended consequences . Milbank Quarterly , 89 ( 3 ) : 450 – 502 .
   PubMed Web of Science ®Google Scholar
• Kesselheim , A. S. , Myers , J. A. and Avorn , J. 2011 . Characteristics of clinical trials to support approval of orphan vs. nonorphan drugs for cancer . JAMA: The Journal of the American Medical Association , 305 ( 22 ) : 2320 – 2326 .
   PubMed Web of Science ®Google Scholar
• Kesselheim , A. S. and Solomon , D. H. 2010 . Incentives for drug development: The curious case of Colchicine . The New England Journal of Medicine , 362 ( 22 ) : 2045 – 2047 .
   PubMed Web of Science ®Google Scholar
• Kirby , T. 2012 . Australia makes up for lost time on rare diseases . The Lancet , 379 ( 9827 ) : 1689 – 1690 .
   PubMed Web of Science ®Google Scholar
• Lang , T. , Hill , A. V. S. , McShane , H. , Shah , R. , Towse , A. , Pritchard , C. and Garau , M. 2005 . New Tb vaccine granted orphan drug status . BMJ: British Medical Journal , 331 ( 7530 ) : 1476
   PubMed Web of Science ®Google Scholar
• Law , M. R. , Kawasumi , Y. and Morgan , S. G. 2011 . Despite law, fewer than one in eight completed studies of drugs and biologics are reported on time on ClinicalTrials.gov . Health Affairs , 30 ( 12 ) : 2338 – 2345 .
   Web of Science ®Google Scholar
• Lehoux , P. , Williams-Jones , B. , Miller , F. , Urbach , D. and Tailliez , S. 2008 . What leads to better health care innovation? Arguments for an integrated policy-oriented research agenda . Journal of Health Services Research & Policy , 13 ( 4 ) : 251 – 254 .
   PubMed Web of Science ®Google Scholar
• Lexchin , J. 2012 . New drugs and safety: What happened to new active substances approved in Canada between 1995 and 2010? . Archives of Internal Medicine , : 1 – 2 .
   Google Scholar
• Light , D. W. and Lexchin , J. R. 2012 . Pharmaceutical research and development: What do we get for all that money? . BMJ , 345 ( 1 ) : e4348 – e4348 .
   PubMedGoogle Scholar
• Light , D. W. and Warburton , R. 2011 . Demythologizing the high costs of pharmaceutical research . Biosocieties , 6 ( 1 ) : 34 – 50 .
   Web of Science ®Google Scholar
• Loughnot , D. 2005 . Potential interactions of the Orphan Drug Act and pharmacogenomics: A flood of orphan drugs and abuses . Am. J. L. and Med. , 31 : 365
   PubMed Web of Science ®Google Scholar
• Maher , P. D. and Haffner , M. 2006 . Orphan drug designation and pharmacogenomics: Options and opportunities . BioDrugs , 20 ( 2 ) : 71
   PubMed Web of Science ®Google Scholar
• McCabe , C. , Claxton , K. and Tsuchiya , A. 2005 . Orphan drugs and the Nhs: Should we value rarity? . BMJ: British Medical Journal , 331 ( 7523 ) : 1016 – 1019 .
   PubMed Web of Science ®Google Scholar
• Meekings , K. N. , Williams , C. S. M. and Arrowsmith , J. E. 2012 . Orphan drug development: An economically viable strategy for Biopharma R&D . Drug Discovery Today , 17 ( 13-14 ) : 660 – 664 .
   PubMed Web of Science ®Google Scholar
• Menon , D. and Stafinski , T. 2008 . Engaging the public in priority-setting for health technology assessment: Findings from a Citizens’ Jury . Health Expectations: An International Journal of Public Participation in Health Care and Health Policy , 11 ( 3 ) : 282 – 293 .
   PubMed Web of Science ®Google Scholar
• Menon , D. and Stafinski , T. 2011 . Role of patient and public participation in health technology assessment and coverage decisions . Expert Review of Pharmacoeconomics and Outcomes Research , 11 ( 1 ) : 75 – 89 .
   PubMed Web of Science ®Google Scholar
• Menon , D. , Stafinski , T. and Martin , D. 2007 . Priority-setting for healthcare: Who, how, and is it fair? . Health Policy (Amsterdam, Netherlands) , 84 ( 2–3 ) : 220 – 233 .
   PubMed Web of Science ®Google Scholar
• Michaux , G. 2010 . EU orphan regulation: Ten years of application . Food and Drug Law Journal , 65 : 639 – 669 .
   Web of Science ®Google Scholar
• Milne , C.-P. and Tait , J. 2009 . Evolution along the Government--Governance continuum: FDA's orphan products and fast track programs as exemplars of what works for innovation and regulation . Food and Drug Law Journal , 64 : 733
   Web of Science ®Google Scholar
• Mitsumoto , J. , Dorsey , E. R. , Beck , C. A. , Kieburtz , K. and Griggs , R. C. 2009 . Pivotal studies of orphan drugs approved for neurological diseases . Annals of Neurology , 66 ( 2 ) : 184 – 190 .
   PubMed Web of Science ®Google Scholar
• Morgan , S. G. , Bassett , K. L. , Wright , J. M. , Evans , R. G. , Barer , M. L. , Caetano , P. A. and Black , C. D. 2005 . ‘Breakthrough’ drugs and growth in expenditure on prescription drugs in Canada . BMJ (Clinical Research Ed.) , 331 ( 7520 ) : 815 – 816 .
   PubMed Web of Science ®Google Scholar
• Narukawa , M. 2001 . Japanese approach to orphan products . The European Regulation on Orphan Medicinal Products , : 41
   Google Scholar
• Network, The Cancer Genome Atlas . 2012 . Comprehensive molecular portraits of human breast tumours . Nature , 490 ( 7418 ) : 61 – 70 .
   PubMed Web of Science ®Google Scholar
• Orphan Drug Act of 1983, Pub. L. No. 97-414, 96 Stat. 2049
   Google Scholar
• Orphan Drug Regulations, 57 Fed. Reg. 62,076, 62,081 (Dec. 29, 1992)
   Google Scholar
• Panju , A. H. and Bell , C. M. 2010 . Policy alternatives for treatments for rare diseases . Canadian Medical Association Journal , 182 ( 17 ) : E787 – E792 .
   Web of Science ®Google Scholar
• Peterson , M. , Hollis , A. and Pogge , T. 2010 . A critique in need of critique . Public Health Ethics , 3 ( 2 ) : 178 – 185 .
   Google Scholar
• Pinxten , W. , Denier , Y. , Dooms , M. , Cassiman , J.-J. and Dierickx , K. 2012 . A fair share for the orphans: Ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation . Journal of Medical Ethics , 38 ( 3 ) : 148 – 153 .
   PubMed Web of Science ®Google Scholar
• Pogge , T. W. 2005 . Human rights and global health: A research program . Metaphilosophy , 36 ( 1-2 ) : 182 – 209 .
   Web of Science ®Google Scholar
• Rai , A. K. 2002 . Pharmacogenetic interventions, orphan drugs, and distributive justice: The role of cost-benefit analysis . Social Philosophy and Policy , 19 ( 2 ) : 246 – 270 .
   PubMed Web of Science ®Google Scholar
• Reinecke , M. , Rommel , K. and Schmidtke , J. 2011 . Funding of rare disease research in Germany: A pilot study . Journal of Community Genetics , 2 ( 2 ) : 101 – 105 .
   Google Scholar
• Rinaldi , A. 2005 . Adopting an orphan . EMBO Reports , 6 ( 6 ) : 507 – 510 .
   PubMed Web of Science ®Google Scholar
• Sekeres , M. , Gold , J. L. , Chan , A.-W. , Lexchin , J. , Moher , D. , Van Laethem , M. L. P. , Maskalyk , J. , Ferris , L. , Taback , N. and Rochon , P. A. 2008 . Poor reporting of scientific leadership information in clinical trial registers . PLoS ONE , 3 ( 2 ) : e1610
   PubMed Web of Science ®Google Scholar
• Seoane-Vazquez , E. , Rodriguez-Monguio , R. , Szeinbach , S. and Visaria , J. 2008 . Incentives for orphan drug research and development in the United States . Orphanet Journal of Rare Diseases , 3 ( 1 ) : 33
   PubMed Web of Science ®Google Scholar
• Sharma , A. , Jacob , A. , Tandon , M. and Kumar , D. 2010 . Orphan drug: Development trends and strategies . Journal of Pharmacy and Bioallied Sciences , 2 ( 4 ) : 290 – 299 .
   PubMedGoogle Scholar
• Silversides , A. 2010 . Federal Committee to review appointment of Pfizer vice-president to CIHR Governing Council . CMAJ : Canadian Medical Association Journal , 182 ( 1 ) : E33 – E34 .
   PubMed Web of Science ®Google Scholar
• Simoens , S. 2011 . Pricing and reimbursement of orphan drugs: The need for more transparency . Orphanet Journal of Rare Diseases , 6 : 42
   PubMed Web of Science ®Google Scholar
• Spilker , B. 1986 . “ The development of orphan drugs: an industry perspective ” . In Orphan Diseases and Orphan Drugs , Edited by: Scheinberg , I. H. and Walshe , J. M. 119 – 134 . Manchester University Press . 1986
   Google Scholar
• Stafinski , T. , McCabe , C. J. and Menon , D. 2010 . Funding the unfundable: Mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems . PharmacoEconomics , 28 ( 2 ) : 113 – 142 .
   PubMed Web of Science ®Google Scholar
• Stallings , S. C. , Huse , D. , Finkelstein , S. N. , Crown , W. H. , Witt , W. P. , Maguire , J. , Hiller , A. J. , Sinskey , A. J. and Ginsburg , G. S. 2006 . A framework to evaluate the economic impact of pharmacogenomics . Pharmacogenomics , 7 ( 6 ) : 853 – 862 .
   PubMed Web of Science ®Google Scholar
• Standing Senate Committee on Social Affairs, Science and Technology. (2012). Canada's Clinical Trial Infrastructure: A Prescription for Improved Access to New Medicines. November 2012. http://www.parl.gc.ca/Content/SEN/Committee/411/SOCI/DPK/01nov12/home-e.htm (http://www.parl.gc.ca/Content/SEN/Committee/411/SOCI/DPK/01nov12/home-e.htm) (Accessed: 11 June 2013 ).
   Google Scholar
• Standing Senate Committee on Social Affairs, Science and Technology. (2013). Prescription Pharmaceuticals in Canada: Post-Approval Monitoring of Safety and Effectiveness. March 2013. http://parl.gc.ca/Content/SEN/Committee/411/SOCI/rep/rep20mar13-e.pdf (http://parl.gc.ca/Content/SEN/Committee/411/SOCI/rep/rep20mar13-e.pdf) (Accessed: 11 June 2013 ).
   Google Scholar
• Tansey , K. E. , Guipponi , M. , Perroud , N. , Bondolfi , G. , Domenici , E. , Evans , D. and Hall , S. K. 2012 . Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: A genome-wide analysis of individual-level data and a meta-analysis . PLoS Med. , 9 ( 10 ) : e1001326
   PubMed Web of Science ®Google Scholar
• Thamer , M. , Brennan , N. and Semansky , R. 1998 . A cross-national comparison of orphan drug policies: Implications for the U.S. Orphan Drug Act . Journal of Health Politics, Policy and Law , 23 ( 2 ) : 265 – 290 .
   PubMed Web of Science ®Google Scholar
• TRIPS. WTO Agreement on Trade-Related Aspects of Intellectual Property Rights, 15 April 1994, 33 I.L.M. 1197
   Google Scholar
• Trotta , F. , Leufkens , H. G. M. , Schellens , J. H. M. , Laing , R. and Tafuri , G. 2011 . Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: When differences have an impact on clinical practice . Journal of Clinical Oncology , 29 ( 16 ) : 2266 – 2272 .
   PubMed Web of Science ®Google Scholar
• Trouiller , P. , Torreele , E. , Olliaro , P. , White , N. , Foster , S. , Wirth , D. and Pécoul , B. 2001 . Drugs for neglected diseases: A failure of the market and a public health failure? . Tropical Medicine and International Health , 6 ( 11 ) : 945 – 951 .
   PubMed Web of Science ®Google Scholar
• Tyers , M. , Brown , E. , Andrews , D. W. , Bergeron , J. J. M. , Boone , C. , Bremner , R. and Bussey , H. A. 2005 . Problems with co-funding in Canada . Science (New York, N.Y.) , 308 ( 5730 ) : 1867
   PubMed Web of Science ®Google Scholar
• Valverde , A. M. , Reed , S. D. and Schulman , K. A. 2012 . Proposed ‘Grant-And-Access’ Program with price caps could stimulate development of drugs for very rare diseases . Health Affairs , 31 ( 11 ) : 2528 – 2535 .
   Web of Science ®Google Scholar
• Vera-Badillo , F. E. , Shapiro , R. , Ocana , A. , Amir , E. and Tannock , I. F. 2013 . Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer . Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO , 24 ( 5 ) : 1238 – 1244 .
   Web of Science ®Google Scholar
• Viergever , R. F. and Ghersi , D. 2011 . The quality of registration of clinical trials . PloS One , 6 ( 2 ) : e14701
   PubMed Web of Science ®Google Scholar
• Warren , K. S. 1986 . “ The great neglected diseases of mankind, or All the world's an orphanage ” . In Orphan Diseases and Orphan Drugs , Edited by: Scheinberg , I. H. and Walshe , J. M. 169 – 176 . Manchester University Press . 1986
   Google Scholar
• Waxman , H. A. 1986 . “ The history and development of the Orphan Drug Act ” . In Orphan Diseases and Orphan Drugs , Edited by: Scheinberg , I. H. and Walshe , J. M. 135 – 145 . Manchester University Press . 1986
   Google Scholar
• Wellman-Labadie , O. and Zhou , Y. 2010 . The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity? . Health Policy , 95 ( 2-3 ) : 216 – 228 .
   PubMed Web of Science ®Google Scholar
• Winquist , E. , Bell , C. M. , Clarke , J. T. R. , Evans , G. , Martin , J. , Sabharwal , M. , Gadhok , A. , Stevenson , H. and Coyle , D. 2012 . An evaluation framework for funding drugs for rare diseases . Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research , 15 ( 6 ) : 982 – 986 .
   PubMed Web of Science ®Google Scholar
• Yin , W. 2008 . Market incentives and pharmaceutical innovation . Journal of Health Economics , 27 ( 4 ) : 1060 – 1077 .
   PubMed Web of Science ®Google Scholar
• Yin , W. 2009 . R&D policy, agency costs and innovation in personalized medicine . Journal of Health Economics , 28 ( 5 ) : 950 – 962 .
   PubMed Web of Science ®Google Scholar